retatrutide needles has become the first obesity drug to report 30.3% average weight loss. But that headline needs context. The result came from a 104-week extension involving participants who began with a BMI improve skin firmness Program:Monthly GLP-1 agonists may interfere

retatrutide needles has become the first obesity drug to report 30.3% average weight loss. But that headline needs context. The result came from a 104-week extension involving participants who began with a BMI improve skin firmness Program:Monthly GLP-1 agonists may interfere

GLP-1 agonists may interfere with cancer imaging, new study finds

Without medical oversight, patients may experience: Excessive nausea or vomiting Dehydration and electrolyte imbalances Muscle loss instead of fat loss Plateaus from improper dosing or escalation Worsening of underlying conditions like GERD, gallbladder issues, or thyroid concerns A physician-supervised program evaluates your full health picture , not just your weight

improve skin firmness

Program:Monthly

10.1002/2211-5463.13499 12 ChopraS.GiovanelliP.Alvarado-VazquezP